At a glance
- Originator Novartis
- Class Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 07 Sep 2001 No-Development-Reported for Anxiety disorders in Switzerland (Unknown route)